Navigation Links
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP,by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it was informed late Wednesday, March 07, 2007, by the Department of Health & Human Services (HHS) that NEUMUNE(R), the Company's product candidate for the treatment of Acute Radiation Syndrome (ARS) was found technically unacceptable and was no longer in the competitive range for the Request for Proposal (RFP) No. DHHS-ORDC-DDA-05-12 entitled, "Medical Countermeasures to Mitigate or Treat Neutropenia Alone or in Combination with Co-Morbidities Associated with Acute Radiation Syndrome (ARS)." No other rationale was provided. Further, Hollis-Eden was notified that HHS had cancelled the solicitation in its entirety.

The Company was surprised by this decision by HHS. In June 2006, based on HHS' evaluation of the Company's technical and cost proposal, HHS informed the Company that its proposal for NEUMUNE was within the competitive range. HHS reaffirmed this decision in October 2006, and Hollis-Eden believes that as of that time its proposal was the only proposal still being considered by HHS. Since that time, HHS has not requested any additional safety or efficacy data on NEUMUNE that had not previously been provided in detailed or summary form. Therefore, the Company is unable to comprehend how NEUMUNE can no longer meet the technical requirements of the solicitation.

"Given the nature and stage of our communications with HHS regarding our original ARS proposal and subsequent revisions, this decision by HHS to exclude our proposal and cancel the RFP is shocking and difficult to understand," stated Richard B. Hollis, Chairman and Chief Executive Officer of Hollis-Eden. "While we will attempt to gain a better understanding from HHS why this determination was made, we clearly met all of the very detailed requirements of the solicitation. NEUMUNE is the only agent ever to have shown the ability to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/1/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the three months ended March ... in Canadian dollars unless otherwise stated. ... despite its limited financial resources," stated Mr. ...
(Date:6/1/2015)... 2015 The nuclear imaging market is estimated ... CAGR of 12.08%. Nuclear medicine is the use of ... types of Nuclear imaging used commonly are PET and ... for nuclear medicine applications like nuclear cardiology procedures. However, ... global shortage of molybdenum-99 isotope which is in turn ...
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
Breaking Medicine Technology:Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3
... Mich., Jan. 20, 2011 Perrigo Company (Nasdaq: PRGO; ... agreement to acquire substantially all of the assets of ... marketer of generic pharmaceutical products for approximately $540 million ... benefit as a result of the acquisition of Paddock,s ...
... Reportlinker.com announces that a new market research report ... Hospital Radiography & Fluoroscopy Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
Cached Medicine Technology:Perrigo to Acquire Assets of Paddock Labs for $540 Million 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 3Perrigo to Acquire Assets of Paddock Labs for $540 Million 4Perrigo to Acquire Assets of Paddock Labs for $540 Million 5Reportlinker Adds Hospital Radiography & Fluoroscopy Census 2
(Date:6/1/2015)... Texas (PRWEB) June 01, 2015 Unlike most ... as three times for in-use periods compared to when the ... monthly rate whether the client uses the generator or not. ... availability and delivery in as little as a few hours ... desire to store a portable generator onsite. , “Even minor ...
(Date:6/1/2015)... On May 14, 2015, the ... the Cherry Creek Chamber of Commerce for the grand ... centers typically do not offer primary care services by ... Creek Urgent Care staff to schedule family care procedures, ... to 7:30 p.m. the center hosted presidents, CEOs, and ...
(Date:6/1/2015)... June 01, 2015 Sharenote, a leading ... for the Healthcare Industry this week in Louisiana. The ... in four days to provide potential providers with the ... profitability, and monitor risk within their network. , ... and is being used by more than 250 practices. ...
(Date:6/1/2015)... There’s never a good time to be ... non-emergency, minor illnesses. , As of June 1, OSF HealthCare ... medical care via the Internet. Patients throughout Illinois can access ... , “Everyone is busy. We know that getting in to ... want to make it easier,” said Jeffry Tillery, MD, Chief ...
(Date:6/1/2015)... Hexagon Geospatial is pleased to announce the launch ... service that provides on-demand access to the company’s world-class ... IMAGINE and GeoMedia are now available ... subscription model for delivering software products as an online ... quickly and easily access the right tools that help ...
Breaking Medicine News(10 mins):Health News:Worldwide Power Products Offers “Budget Billing” Contingency Generator Rental Program; Guarantees Power for Peak of Hurricane Season and Beyond 2Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3
... the drug Tamiflu to avert the bird flu outbreak ... February 2006//. ,Scientists at the High Security ... and genetic analysis of virus collected from Jalgaon and ... to Tamiflu due the different types of amino acids ...
... Integrated Counselling and Testing Centres at Government General Hospitals ... with the Indian Public Health Standards (IPHS), draft guidelines ... aim to spread awareness about AIDS in the susceptible ... 2006 report on the global AIDS epidemic, 486 fresh ...
... month, The Medicines and Healthcare products Regulatory Agency ... amendment it is now possible to market homoeopathic ... and therapeutic application of remedies in question. This ... who have written off homoeopathy as ‘mumbo jumbo’ ...
... from Drexel University and the University of Brighton in ... improve the treatment of sepsis. // ... or severe trauma that results in 1,500 deaths worldwide ... lung and breast cancers. Sepsis occurs when proteins called ...
... Jude Children's Research Hospital have discovered in mouse models ... earliest critical regulators // controlling lens development in the ... have been previously identified in patients with holoprosencephaly, a ... called the cerebrum to fail to divide normally into ...
... of cognitive decline experienced by several cancer patients receiving ... on the // effect of chemotherapy on cognitive functions ... Baycrest Research Centre for Aging and the Brain carried ... Drs. Ian Tannock and Janette Vardy of Princess Margaret ...
Cached Medicine News:Health News:Bird flu outbreak prevented by Tamiflu 2Health News:Anti-HIV drive intensified in Haryana 2Health News:Hostility breeds against Homeopathy in England following new regulations 2Health News:Drexel Research in Cytokines Could Treat Sepsis 2Health News:Key Gene Controlling Eye Lens Development Identified 2Health News:Chemo drugs cause cognitive decline in breast cancer patients 2
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the direct colorimetric determination of alkaline phosphatase in human serum....
Medicine Products: